Value
6.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 6.0 |
RAPP · Why this verdict
Why Rapport Therapeutics (RAPP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Rapport Therapeutics is a clinical-stage biotech with strong analyst conviction at a price target implying 49% upside and a 3-for-4 earnings beat streak averaging 9.9% positive surprise, but the company burns cash at -247% of revenue, carries a quality score of 1.9 out of 10, and an extremely elevated put/call ratio of 4.36 signals heavy bearish options activity.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts rate Rapport Therapeutics with an average score of 8.15 out of 10 and a price target implying 49% upside to $49.68, reflecting strong sell-side conviction in the pipeline potential, particularly given the company's focus on precision neuroscience therapeutics. Sentiment breakdown | The stock price rises above $43 within 12 months as clinical trial data validates the analyst thesis. | ↑Improving |
| CounterWith only 10 analysts covering the stock (light coverage) and the signal dampened as a result, the consensus target may overstate the breadth of institutional conviction in the clinical thesis. | ||
A put/call ratio of 4.36 is extremely elevated, meaning more than four times as many puts as calls are outstanding, signaling that options market participants are positioned heavily for downside — the most bearish options signal in this data set. Key risks | The put/call ratio declines below 2.0 following positive clinical data announcements that reduce the perceived downside risk. | →Stable |
| CounterExtremely high put/call ratios in small-cap biotech stocks can reflect binary event hedging around upcoming clinical readouts rather than outright directional bearish bets, and a positive outcome can cause a rapid unwind. | ||
With free cash flow at -247% of revenue and a quality score of 1.9 out of 10 — below the minimum 4.0 threshold — the company fails the investability quality screen and requires significant external financing to sustain operations while its clinical programs mature. Warnings | The company announces a non-dilutive financing event or partnership that extends its cash runway by at least 18 months. | →Stable |
| CounterClinical-stage biotech companies routinely operate below quality thresholds during development phases; the negative free cash flow reflects planned investment in the pipeline rather than operational inefficiency. | ||
Rapport has beaten earnings per share estimates in 3 of the last 4 quarters with an average positive surprise of 9.9%, including a 40.7% beat in May 2026 when actual losses were -$0.42 against an estimate of -$0.71, suggesting cash management is better than modeled. Earnings | The company beats earnings estimates in at least 2 of the next 3 quarters with average positive surprise above 5%. | ↓Deteriorating |
| CounterA single miss of -6.8% in March 2026 and highly variable surprises across quarters suggest the earnings beats reflect forecasting imprecision at low absolute values rather than underlying operating leverage. | ||
Analysts rate Rapport Therapeutics with an average score of 8.15 out of 10 and a price target implying 49% upside to $49.68, reflecting strong sell-side conviction in the pipeline potential, particularly given the company's focus on precision neuroscience therapeutics.
↑ImprovingSentiment breakdown
- Expectation
- The stock price rises above $43 within 12 months as clinical trial data validates the analyst thesis.
CounterWith only 10 analysts covering the stock (light coverage) and the signal dampened as a result, the consensus target may overstate the breadth of institutional conviction in the clinical thesis.
A put/call ratio of 4.36 is extremely elevated, meaning more than four times as many puts as calls are outstanding, signaling that options market participants are positioned heavily for downside — the most bearish options signal in this data set.
→StableKey risks
- Expectation
- The put/call ratio declines below 2.0 following positive clinical data announcements that reduce the perceived downside risk.
CounterExtremely high put/call ratios in small-cap biotech stocks can reflect binary event hedging around upcoming clinical readouts rather than outright directional bearish bets, and a positive outcome can cause a rapid unwind.
With free cash flow at -247% of revenue and a quality score of 1.9 out of 10 — below the minimum 4.0 threshold — the company fails the investability quality screen and requires significant external financing to sustain operations while its clinical programs mature.
→StableWarnings
- Expectation
- The company announces a non-dilutive financing event or partnership that extends its cash runway by at least 18 months.
CounterClinical-stage biotech companies routinely operate below quality thresholds during development phases; the negative free cash flow reflects planned investment in the pipeline rather than operational inefficiency.
Rapport has beaten earnings per share estimates in 3 of the last 4 quarters with an average positive surprise of 9.9%, including a 40.7% beat in May 2026 when actual losses were -$0.42 against an estimate of -$0.71, suggesting cash management is better than modeled.
↓DeterioratingEarnings
- Expectation
- The company beats earnings estimates in at least 2 of the next 3 quarters with average positive surprise above 5%.
CounterA single miss of -6.8% in March 2026 and highly variable surprises across quarters suggest the earnings beats reflect forecasting imprecision at low absolute values rather than underlying operating leverage.
Per-dimension breakdown
Quality
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -280% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.7 |
- ▸Overbought (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 8.4 |
| Price target | 7.9 |
- ▸LLM news sentiment: +0.80 (n=1)
- ▸Analyst upside: 22%
Insider
3.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 4.1 |
- ▸Modest insider selling — $1,815,385 (0.081% of mkt cap)
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.7 |
| growth rank | 5.0 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.3 |
| 52w position | 9.9 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.5 |
| days to cover | 4.6 |
| volatility | 0.3 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 7.2 |
| debt equity | 9.9 |
- ▸Elevated put/call: 4.62
- ▸High IV: 95%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 4.6 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:7.2>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.80
- EARNINGS_PROXIMITY:85d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.4<1.5@spot
Warning (0)
none
Reward-to-Risk
0.41
Upside
+6.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's 0.4<1.5@spot outcome against Sentiment at 8.4 and asymmetric R:R of 0.41.
The strongest dimensions are Sentiment at 8.4, Momentum at 7.2, and Value at 6.0; the weakest are Quality at 2.0, Technical at 3.4, and Insider at 3.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.41 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Analyst Conviction Upside
Trip ifAnalyst consensus price target declines below $38, eliminating the upside margin to the current price.
- P2Extreme Put Call Ratio
Trip ifThe put/call ratio rises above 6.0, extending the extreme bearish options positioning further.
- P3Cash Burn Quality Floor Breach
Trip ifCash burn worsens beyond -400% of revenue in any reported period.
- P4Earnings Beat Execution
Trip ifEPS surprise falls below -20% in at least 2 of the next 4 quarters.